Pfiz­er bags a Langer plat­form, buys Bind as­sets with a $40M bid

In the end, Pfiz­er saw the most val­ue in Bind Ther­a­peu­tics’ plat­form tech­nol­o­gy. Al­ready part­nered on new prod­ucts, Pfiz­er has come up with a win­ning bid of $40 mil­lion for the trou­bled biotech’s as­sets.

Pfiz­er grabbed “sub­stan­tial­ly all” of the Cam­bridge, MA-based biotech’s as­sets out of a Chap­ter 11 auc­tion, ac­cord­ing to a state­ment. And NanoCar­ri­er came in with the run­ner up of­fer for the as­sets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER